Insider Monkey On $PSTI Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Number of Hedge Fund Holders: 4
Share Price as of April 5: $2.11
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is an Israel-based biotechnology company that works to develop and research cell therapeutic products for the treatment of ischemic, inflammatory, and hematologic conditions, in addition to autoimmune disorders.
On March 2, Pluristem Therapeutics Inc. (NASDAQ:PSTI) issued an update to its shareholders, and the CEO stated that he is confident about the direction that Pluristem Therapeutics Inc. (NASDAQ:PSTI) has taken. The cell expansion platform has the potential for high demand in the medical field and the company also announced its partnership with Tnuva, Israel's largest food producer, to develop cultured food. Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s cutting edge technology and expertise could make it a leader in this space, and it aims to launch raw meat products in 2023. An additional clinical hematological study is expected later in 2022 that will advance the creation of next generation products using CRISPR and induction technologies.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced on March 23 positive final results from its innovative hematology Phase I study to evaluate the safety and exploratory efficacy of intramuscular injections of PLX-R18, which works to improve the regenerative potential of the bone marrow. The FDA's recognition of PLX-R18's potential to treat Acute Radiation Syndrome (ARS) is also notable. This treatment potentially carries great significance for current events in Ukraine and Europe, providing hope for treatment in the case of a nuclear war. Pluristem Therapeutics Inc. (NASDAQ:PSTI) believes that this treatment will promote well being, improve the standard of care, and likely save lives.
Among the hedge funds tracked by Insider Monkey at the end December 2021, 4 funds reported owning stakes in Pluristem Therapeutics Inc. (NASDAQ:PSTI), compared to 6 funds in the earlier quarter. Cathie Wood’s ARK Investment Management is the largest shareholder of the company, with more than 1 million shares worth $1.5 million.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is on the radar of elite hedge funds, just like Moderna, Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), and Amgen Inc. (NASDAQ:AMGN).
https://finance.yahoo.com/news/10-biotech-penny-stocks-growth-141547173.html